Meropenem powder for solution for injection 1 g vial No. 1

Meropenem powder for solution for injection is indicated for the treatment of infections in adults and children aged 3 months and older:

Composition

Active ingredient: meroenem;

1 vial contains meropenem trihydrate equivalent to 0.5 g or 1 g of meropenem anhydrous;

Excipients: sodium carbonate anhydrous.

Contraindication

Method of application

Meropenem should usually be administered as an infusion over 15 to 30 minutes.

Alternatively, doses up to 1 g can be administered as a bolus injection over 5 minutes. There are limited safety data on the administration of 2 g as a bolus injection in adults.

Application features

Pregnant women

Not recommended.

Children

The drug is used in children aged 3 months and older.

Drivers

Studies of the effect of the drug on the ability to drive vehicles or other mechanisms have not been conducted.

Overdose

Relative overdose is possible in patients with impaired renal function if the dose is not adjusted. Some post-marketing experience suggests that if adverse reactions occur after overdose, they are consistent with the profile of adverse reactions listed below, and are usually mild in severity and resolve after discontinuation of the drug or dose reduction. Symptomatic treatment should be considered.

In individuals with normal kidney function, the drug is rapidly excreted by the kidneys.

Hemodialysis removes meropenem and its metabolites from the body.

Side effects

Interaction

Concomitant use with carbapenems has been reported to decrease blood valproic acid levels by 60-100% within approximately 2 days. Due to the rapid onset of action and the extent of the decrease, concomitant use of valproic acid and carbapenems is considered uncorrectable and should be avoided.

Storage conditions

Store at a temperature not exceeding 25 °C in the original packaging. Do not freeze.

Keep out of reach of children.

Shelf life - 3 years.